Successful Retreatment Using Pembrolizumab for Non–small-cell Lung Cancer After Severe Immune-related Hepatitis: A Case Report

Keigo Kobayashi; Ichiro Nakachi; Akifumi Mitsuishi; Daisuke Arai; Kaori Sakurai; Katsunori Masaki; Atsushi Chiyotani; Hidenori Takahashi; Toshiyuki Tahara; Kenzo Soejima

doi:10.1016/j.cllc.2019.02.004

Successful Retreatment Using Pembrolizumab for Non–small-cell Lung Cancer After Severe Immune-related Hepatitis: A Case Report

Keigo Kobayashi, Ichiro Nakachi, Akifumi Mitsuishi, Daisuke Arai, Kaori Sakurai, Katsunori Masaki, Atsushi Chiyotani, Hidenori Takahashi, Toshiyuki Tahara, Kenzo Soejima

研究成果: Article › 査読

2 被引用数 (Scopus)

本文言語	English
ページ（範囲）	e30-e32
ジャーナル	Clinical Lung Cancer
巻	21
号	1
DOI	https://doi.org/10.1016/j.cllc.2019.02.004
出版ステータス	Published - 2020 1月

ASJC Scopus subject areas

腫瘍学
呼吸器内科
癌研究

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

文献へのアクセス

10.1016/j.cllc.2019.02.004

他のファイルとリンク

引用スタイル

@article{ee2f6e66364d4a50bdf79ddf868d0762,

title = "Successful Retreatment Using Pembrolizumab for Non–small-cell Lung Cancer After Severe Immune-related Hepatitis: A Case Report",

keywords = "Immune-related adverse events, Immunotherapy, NSCLC, PD-1 inhibitors, Severe hepatitis",

author = "Keigo Kobayashi and Ichiro Nakachi and Akifumi Mitsuishi and Daisuke Arai and Kaori Sakurai and Katsunori Masaki and Atsushi Chiyotani and Hidenori Takahashi and Toshiyuki Tahara and Kenzo Soejima",

year = "2020",

month = jan,

doi = "10.1016/j.cllc.2019.02.004",

language = "English",

volume = "21",

pages = "e30--e32",

journal = "Clinical Lung Cancer",

issn = "1525-7304",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - Successful Retreatment Using Pembrolizumab for Non–small-cell Lung Cancer After Severe Immune-related Hepatitis

T2 - A Case Report

AU - Kobayashi, Keigo

AU - Nakachi, Ichiro

AU - Mitsuishi, Akifumi

AU - Arai, Daisuke

AU - Sakurai, Kaori

AU - Masaki, Katsunori

AU - Chiyotani, Atsushi

AU - Takahashi, Hidenori

AU - Tahara, Toshiyuki

AU - Soejima, Kenzo

PY - 2020/1

Y1 - 2020/1

KW - Immune-related adverse events

KW - Immunotherapy

KW - NSCLC

KW - PD-1 inhibitors

KW - Severe hepatitis

UR - http://www.scopus.com/inward/record.url?scp=85074683829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074683829&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2019.02.004

DO - 10.1016/j.cllc.2019.02.004

M3 - Article

C2 - 31699508

AN - SCOPUS:85074683829

SN - 1525-7304

VL - 21

SP - e30-e32

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

IS - 1

ER -